I have learned today of a whole new class of antipsychotics that do not act on dopamine receptors.
Cobenfy was approved in 2024 by the FDA.
FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia | FDA
Other drugs in this class are in development.
NeuRA | Understanding Cobenfy: A conversation with NeuRA’s Dr Tertia….
For now, the approval is for Schizophrenia, but often antipsychotics are approved for Schizophrenia first, for Bipolar second, and as an adjunct treatment for MDD third.
__________________
Bipolar I w/psychotic features
Last inpatient stay in 2018
Lybalvi 10 mg
Naltrexone 75 mg
Gabapentin 1500 mg+Vitamin B-complex (against extrapyramidal side effects)
Long-term side effects from medications, some of them discontinued:
- Hypothyroidism
- Obesity BMI ~ 38
|